Phase 3 Gout and Hyperuricemia Study

Now Enrolling in Banning, Boise, Norfolk, Portsmouth, Salt Lake City, and Vestal

Now Enrolling

About this research study

Gout is a common form of inflammatory arthritis that can be very painful. Symptoms can fluctuate in intensity from flares to relatively no symptoms (remission). Hyperuricemia, or an elevated level of uric acid in the blood, may exist for many years before the first clinical attack of gout. Sustained hyperuricemia is the precursor of gout.

Velocity is seeking participants with hyperuricemia and gout for a Phase 3 clinical trial for an investigational medication for the condition.

Eligible participants...

  • Must be age 18 to 85
  • Must have hyperuricemia and a history or presence of gout
  • Must NOT experience an acute gout attack within 2 weeks of screening for the study
  • Must NOT have secondary hyperuricemia
  • Must NOT have received pegloticase
  • Will receive an investigational medication or allopurinol or placebo at no cost
  • Will receive compensation for study-related time
  • Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Velocity enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.

Enter your info

Name(Required)
Date of birth(Required)
Age can help us determine study eligibility (you must be age 18 or older to submit this form).
Race(Required)
Select one or more designations that best describe you. This information can help Velocity better ensure all populations are represented in research.
This field is hidden when viewing the form

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from Velocity and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at info@velocityclinical.com. For full details, refer to Velocity's privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.

This field is for validation purposes and should be left unchanged.

Study Locations

San Bernardino, California • Velocity Clinical Research

650 E. Hospitality Lane, Suite 200, San Bernardino, CA 92408
Phone: (951) 755-0222

Boise (Meridian), Idaho • Velocity Clinical Research

2950 E. Magic View Dr., Suite 100, Meridian, ID 83642
Phone: (208) 377-8653

Norfolk, Nebraska • Velocity Clinical Research

3400 W Norfolk Avenue, Norfolk, NE 68701
Phone: (402) 371-0797

Suffolk, Virginia • Velocity Clinical Research

7007 Harbor View Blvd, Suite 109, Suffolk, VA 23435
Phone: (757) 996-4200

Salt Lake City (West Jordan), Utah • Velocity Clinical Research

3590 West 9000 South, Suite 300, West Jordan, UT 84088
Phone: (801) 542-8190

Vestal, New York • Velocity Clinical Research

4100 Vestal Road, Ste LL-100, Vestal, NY 13850
Phone: (607) 794-5790

©2023 Velocity Clinical Research | All Rights Reserved | Privacy Policy